Carla Greenbaum, MD

Title:

Director of Diabetes Program

Phone Number:

206-515-5232

Background

Dr. Greenbaum received her undergraduate (‘78) and medical (‘81) degrees at Brown University then pursued her endocrinology fellowship at University of Washington, where she continues as clinical faculty. She joined the Benaroya Research Institute (BRI) in 2000, where she is a Member and serves as Director of the Diabetes Research Program and the BRI Clinical Research Center. Dr. Greenbaum serves on the Board of Directors for BRI and is a member of the BRI Institutional Review Board which provides oversight for clinical studies.

Areas of Research

Dr. Greenbaum is an international leader in clinical investigations and trials to prevent or intervene in the diabetes autoimmune disease process. She is the Director of the North American Network of the Type 1 Diabetes Genetic Consortium, an NIH sponsored international study; Vice-Chair of Type 1 Diabetes TrialNet and Principal Investigator of the TrialNet Northwest Clinical Center. Diabetes TrialNet is an National Institutes of Health (NIH) international network which conducts clinical trials to stop Type 1 diabetes. Dr. Greenbaum is a member of the Board of Directors of the Diabetes Vaccine Development Center (Australia), the Clinical Affairs Advisory Committee for the Juvenile Diabetes Research Foundation (JDRF), the Scientific Review Committee of the NIH sponsored Immune Tolerance Network, as well as serving on other NIH, JDRF, and American Diabetes Association (ADA) review committees. She currently serves on the Board of Directors for the Western Washington State ADA.

Selected Publications

Selected Publications:
1. DPT-1 Study Group: Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus. New England Journal of Medicine, 346:1685-1691, 2002.

2. Greenbaum CJ, Harrison LC: Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes, vol 52:1059-1065, 2003.

3. Greenbaum CJ, et al: High Frequency of Abnormal Glucose Tolerance in DQA1*0102/DQB1*0602 Relatives of Patient with Type 1 Diabetes. Diabetologia, Jan;48(1):68-74, 2005

4. Skyler JS, et al: Effects of Oral Insulin in Relatives of Patients with Type 1 Diabetes. Diabetes Care, 28(5):1068-1076, 2005.

5. Seyfert-Margolis V, et al: Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes, Sep;55(9):2588-2594, 2006.

6. Rieck M, et al. Genetic Variation in PTPN22 corresponds to altered function of T and B lymphocytes. J. Immunol. Oct 1;179(7):4704-10, 2007.

7. Xu P, Cuthbertson DD, Greenbaum CJ, Palmer JP, Krischer JP: The Role of Insulin Resistance in Predicting the Progression to Type 1 Diabetes. Diabetes Care, Sep;30(9):2314-20, 2007.

Diabetes Research Program